Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study

•Phase 3 ORIENT-11 performed in China in 1L locally advanced/metastatic nsqNSCLC.•At final OS analysis, sintilimab arm continued to reveal improved OS vs placebo arm.•OS benefit observed across all prespecified subgroups.•OS treatment effect consistent with other PD-1/PD-L1 inhibitors in this indication.•Supports sintilimab as viable anti-PD-1 treatment for nsqNSCLC.